相关实验视频

Updated: Jun 4, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

急性髓性白血病的驱动器突变景观为基于新抗原的免疫治疗提供了洞察力

Peng Jin¹, Jie Shen¹, Ming Zhao²

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

|December 26, 2024

概括

急性髓性白血病 (AML) 免疫疗法受到少数抗原的限制. 这项研究确定了来自驱动突变的新抗原,发现插入/删除的收益更多,影响患者的结果和免疫抑制.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

由于缺乏特定抗原,急性髓性白血病 (AML) 在免疫治疗方面取得了有限的成功.
驱动器突变是潜在的目标,但AML新抗原环境及其免疫影响尚不清楚.

研究的目的:

为了全面描述由驱动器突变产生的AML新抗原景观.
评估新抗原对患者结局和瘤免疫微环境的影响.
为潜在的治疗开发确定可操作的免疫原性新抗原.

主要方法:

对304名AML患者的DNA和RNA测序进行了匹配,并与约2500个额外病例的数据进行了整合.
使用集成的特征和通过体外测试 (MHC结合,ELISpot,四聚合物) 验证的免疫原性进行新抗原预测.
使用转录学,单细胞RNA测序和流细胞测量分析瘤免疫微环境.

主要成果:

确定了49个驱动基因,插入/删除 (indels) 产生了比SNV或融合更多和更高质量的新抗原.
开发了可靠的模型,预测免疫原性新表位,其中20个经过实验验证.
较高的新抗原负载与不良的临床结果,IFN驱动的免疫抑制和CD8+T细胞耗尽相关.

结论:

来自驱动器突变的新抗原为AML免疫疗法提供了有希望的标.
在AML中,英德尔是免疫新抗原的重要来源.
需要采取战略来克服与AML中高新抗原负载相关的免疫抑制.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.艾皮托普的免疫原性免疫抑制的环境新抗原是一种新抗原.T细胞耗尽的情况

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...